In accordance with a decision made by the Annual General Meeting held on May 10, 2012, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September 2012, and the Chairman of the Board.
For the 2013 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders and, accordingly, are members of the Election Committee:
Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Martin Bjäringer, representing his own holding and Hajskäret Invest AB
Under the leadership of the Chairman of the Board, Mats Arnhög, the Election Committee shall prepare proposals for the Board of Directors that are to be presented to and decided upon at the Annual General Meeting on May 15, 2013.
Lund, November 15, 2012
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA primarily for the treatment of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. The company also has one additional project in clinical development, the orally administered compound 57-57 for Systemic Sclerosis. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
www.activebiotech.com
